Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,540,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,324.109 pence per share.
- Treasury Shares Held: 390,312,158 shares (representing 6.92% of total voting rights).
- Shares in Issue: 5,632,781,042 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,540,000 shares on September 12, 2007. Consequently, the total number of shares held in Treasury increased to 390,312,158.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,632,781,042) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (390,312,158) and its percentage of total voting rights (6.92%).
- Review the specific price paid per share (1,324.109 pence) for capital allocation analysis.